The antibiotic was given once a day, through intravenous (IV)-to oral, to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). NUZYRA was officially approved by the US Food and Drug Administration in October of last year, and finally became commercially available in the US on Tuesday (February 5). "Treating skin infections and pneumonia has become increasingly complex due to growing resistance among common pathogens, safety concerns surrounding current antibiotics and the limited availability of oral treatment options," Keith Kaye, MD, MPH and director of research in the division of infectious diseases at the University of Michigan Medical Center, said in Wednesday's release. Kaye added that in terms of pneumonia and skin infections, NUZYRA proved to have an effect against common pathogens, such as pathogens that are resistant to other antibiotic classes.